MedTrace Logo

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

NCT01301066 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2014-04-29

Study results available
· View outcomes & findings →

Summary

A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.

Conditions

Interventions

DRUG

Pitavastatin

Pitavastatin 4 mg QD

DRUG

Pravastatin

Pravastatin 40 mg QD

Sponsors & Collaborators

  • Kowa Pharmaceuticals America, Inc.

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Kowa Research Institute, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301066 on ClinicalTrials.gov